Last reviewed · How we verify
OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer
To study the performance of OCS products based on exosome detection technology in monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment, and to explore reliable methods for monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment.
Details
| Lead sponsor | Beihua Kong |
|---|---|
| Status | NOT_YET_RECRUITING |
| Enrolment | 32 |
| Start date | Mon Sep 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Apr 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Ovarian Cancer